Valuation of the EQ-5D-5L in Taiwan
- PMID: 30586400
- PMCID: PMC6306233
- DOI: 10.1371/journal.pone.0209344
Valuation of the EQ-5D-5L in Taiwan
Erratum in
-
Correction: Valuation of the EQ-5D-5L in Taiwan.PLoS One. 2024 Jun 18;19(6):e0305983. doi: 10.1371/journal.pone.0305983. eCollection 2024. PLoS One. 2024. PMID: 38889178 Free PMC article.
Abstract
Objectives: To date, a value set for the EQ-5D-5L based on the health state preferences of the general Taiwanese population has not been available. This study aimed to develop a Taiwanese value set for EQ-5D-5L to facilitate health technology assessment for medical products and services.
Methods: An international standardized protocol for EQ-5D-5L valuation studies developed by the EuroQol group was adopted. Adult members of the general public were recruited from six geographic regions in Taiwan. In computer-based face-to-face interviews, each participant completed 10 composite time trade-off (C-TTO) tasks and 7 discrete choice experiment (DCE) tasks. The C-TTO and DCE data were modeled alone or in combination (using hybrid models) with additive models containing 20 dummy variables as main effects. The model performance was assessed both quantitatively and qualitatively (mainly logical consistency and prediction patterns).
Results: Of 1,073 recruited participants, 1,000 completed the study. Approximately 13% of observed utility values were -1 in the C-TTO tasks. The hybrid model, using all available data that assumed C-TTO response values left-censored at -1 and with main effects coefficients with logical consistency (monotonicity), was considered as the most appropriate model. The predicted utility ranged from -1.0259 to 1.
Conclusions: An EQ-5D-5L value set was developed for Taiwan using an established study protocol and a representative sample of the general population. This may facilitate health economic evaluations and decision making on resource allocation under Taiwan's national health insurance program in the future.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Ministry of Health and Welfare T. Health Promotion Administration MoHaW: Processing Notice for New Drug Listing and Pricing under National Health Insurance Taipei: National Health Insurance Administration, Ministry of Health and Welfare; 2013. [cited 2017 April 1]. Available from: http://www.rootlaw.com.tw/LawArticle.aspx?LawID=A040170081026400-1020521.
-
- Center for Drug Evaluation T. The Process of HTA Assessment for Applications of NHI New Drug Listing 2013 [cited 2018 April 12]. Available from: http://www.cde.org.tw/eng/HTA/business.
-
- Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43. . - PubMed
-
- Health Promotion Administration MoHaW T. National health interview survey (NHIS) 2015 [cited 2017 April 2]. Available from: http://www.hpa.gov.tw/EngPages/Detail.aspx?nodeid=1077&pid=6198.
